


**AMENDMENTS TO THE CLAIMS**

1. (Withdrawn).

5

2. (Currently amended) A compound of General Formula 2 according to claim 1:



General Formula 2

wherein:

10 Py represents pyridin-4-yl which is disubstituted in positions 2 and 6, whereby the substituent in position 2 is C<sub>1-7</sub>-alkyl or aryl-C<sub>1-7</sub>-alkyl; and the substituent in position 6 is methyl or ethyl;

X represents R<sup>1</sup>-SO<sub>2</sub>NR<sup>2</sup>-; R<sup>1</sup>-CONR<sup>2</sup>-; aryl-R<sup>8</sup>-CONR<sup>2</sup>-; or R<sup>1</sup>-NR<sup>3</sup>CONR<sup>2</sup>-;

Z represents hydrogen;

15 n represents the numbers 0 or 1;

R<sup>1</sup> represents aryl or aryl-C<sub>1-7</sub>-alkyl;

R<sup>2</sup> represents hydrogen; C<sub>1-7</sub>-alkyl; 2-hydroxyethyl; aryl-C<sub>1-7</sub>-alkyl; or a saturated carbocyclic ring;

R<sup>3</sup> represents hydrogen or C<sub>1-7</sub>-alkyl;

20 R<sup>4</sup> represents hydrogen; C<sub>1-7</sub>-alkyl; aryl; aryl-C<sub>1-7</sub>-alkyl; or forms together with R<sup>5</sup> a saturated 4, 5 or 6 membered ring including the nitrogen atom to which R<sup>4</sup> and R<sup>5</sup> are attached as ring atom;

R<sup>5</sup> represents hydrogen; C<sub>1-7</sub>-alkyl; 2-hydroxyethyl; or forms together with R<sup>4</sup> a saturated 4, 5 or 6 membered ring including the nitrogen atom to which R<sup>4</sup> and R<sup>5</sup> are attached as ring atom.

25 R<sup>8</sup> represents a saturated carbocyclic ring;

wherein

aryl means a group selected from the group consisting of 2-furyl; 2-thienyl; phenyl; 2-methylphenyl; 3-methylphenyl; 4-methylphenyl; 2-biphenyl; 3-biphenyl; 4-biphenyl; 2-methoxyphenyl; 3-methoxyphenyl; 4-methoxyphenyl; 3,4-dimethoxyphenyl; 2,6-dimethoxyphenyl; 2,5-dimethoxyphenyl; 2-phenoxyphenyl; 3-phenoxyphenyl; 4-phenoxyphenyl; 2-cyanophenyl; 3-cyanophenyl; 4-cyanophenyl; 2-fluorophenyl; 3-fluorophenyl; 4-fluorophenyl; 2,4-difluorophenyl; 2,5-difluorophenyl; 2,6-difluorophenyl; 3,4-difluorophenyl; 2-chlorophenyl; 3-chlorophenyl; 4-chlorophenyl; 3,4-dichlorophenyl; 2-bromophenyl; 3-bromophenyl; 4-bromophenyl; 2-trifluoromethylphenyl; 3-trifluoromethylphenyl; 4-trifluoromethylphenyl; 3,5-bis-trifluoromethylphenyl; 4-trifluoromethoxyphenyl; 4-ethylphenyl; 4-n-propylphenyl; 2-iso-propylphenyl; 4-iso-propylphenyl; 4-tert-butylphenyl; 4-n-pentylphenyl; 4-bromo-2-ethylphenyl; 2-methanesulfonylphenyl; 3-methanesulfonylphenyl; 4-methanesulfonylphenyl; 4-acetamidophenyl; 4-hydroxyphenyl; 4-iso-propyloxyphenyl; 4-n-butoxyphenyl; 2-methoxy-4-methylphenyl; 4-methoxy-2,3,6-trimethylphenyl; 5-bromo-2-methoxy-phenyl; 2-pyridyl; 3-pyridyl; 4-pyridyl; 1-naphthyl; 2-naphthyl; 4-(pyrrol-1-yl)phenyl; 4-benzoylphenyl; 5-dimethylaminonaphth-1-yl; 5-chloro-3-methylthiophen-2-yl; 5-chloro-3-methyl-benzo[b]thiophen-2-yl; 3-(phenylsulfonyl)-thiophen-2-yl; 2-chloro-thien-5-yl; 2,5-dichloro-thien-3-yl; 4,5-dichlorothien-2-yl; 2-(2,2,2-trifluoroacetyl)-1-2,3,4-tetrahydroisoquinolin-7-yl; 4-(3-chloro-2-cyanophenoxy)phenyl; 2-(5-benzamidomethyl)thiophenyl; 5-quinolyl; 6-quinolyl; 7-quinolyl; 8-quinolyl; (2-acetylamino-4-methyl)thiazol-5-yl; and 1-methylimidazol-4-yl; and

25 aryl-C<sub>1-7</sub>-alkyl means 3-phenylpropyl, phenethyl, benzyl, or benzyl substituted in the phenyl ring with C<sub>1-7</sub>-alkyl, C<sub>1-7</sub>-alkyl-O-, trifluoromethyl or halogen; in free or pharmaceutically acceptable salt form.

3. (Withdrawn).

30 4. (Withdrawn).

5. (Withdrawn).

6. (Withdrawn).

7. (Withdrawn).

8. (Withdrawn).

5 9. (Withdrawn).

10. (Withdrawn).


11. (Withdrawn).

12. (Withdrawn).

13. (Withdrawn).

10

14. (Currently amended) The compound of General Formula 14 according to claim + 2:



15

General Formula 14

wherein aryl, R<sup>2</sup>, n and Py have the meaning given in General Formula 2;


in free or pharmaceutically acceptable salt form.

15. (Withdrawn).

20

16. (Withdrawn).

17. (Currently amended) The compound of General Formula 17 according to claim + 2:



General Formula 17


wherein R<sup>1</sup>, R<sup>2</sup>, n and Py have the meaning given in General Formula 2;

in free or pharmaceutically acceptable salt form.

5

18. (Cancelled).

19. (Currently amended) The compound of General Formula 19 according to claim + 2:




General Formula 19

10

wherein X, Z and n have the meaning given in General Formula 2;

in free or pharmaceutically acceptable salt form.

20. (Currently amended) The compound of General Formula 20 according to claim + 2:



15


General Formula 20

wherein X, Z and n have the meaning given in General Formula 2;

in free or pharmaceutically acceptable salt form.

20

21. (Currently amended) The compound of General Formula 21 according to claim + 2:




General Formula 21

wherein R<sup>1</sup> and R<sup>2</sup> have the meaning given in General Formula 2;

in free or pharmaceutically acceptable salt form.

5

22. (Currently amended) The compound of General Formula 22 according to claim + 2:



General Formula 22

wherein aryl, R<sup>2</sup> and n have the meaning given in General Formula 2;

10 in free or pharmaceutically acceptable salt form.

23 (Withdrawn).

15 24 (Withdrawn).

25. (Withdrawn).

26. (Previously amended ) A compound selected from the group consisting of:

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-*N*-

20 propyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-*N*-propyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-benzenesulfonamide;

25 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-fluoro-benzenesulfonamide;

*N*-Ethyl-4-methoxy-*N*-(1-{2-[3-(2-methyl-6-phenethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

*N*-Ethyl-4-methoxy-*N*-(1-{2-[3-(2-methyl-6-propyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

5 *N*-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-benzenesulfonamide;

2-(4-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide;

10 *N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-benzenesulfonamide;

*N*-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Diethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-benzenesulfonamide;

15 *N*-(1-{2-[3-(2,6-Diethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-fluoro-benzenesulfonamide;

*N*-(1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-*N*-propyl-benzenesulfonamide;

20 4-Bromo-*N*-ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

*N*-(1-{2-[3-(2-Ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-*N*-propyl-benzenesulfonamide;

25 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-*N*-methyl-benzenesulfonamide;

*N*-{4-[(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-sulfamoyl]-phenyl}-acetamide;

30 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-isopropoxy-*N*-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4,*N*-dimethyl-benzenesulfonamide;

4-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-benzenesulfonamide;

3,4-Dichloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-benzenesulfonamide;

5 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-4-trifluoromethyl-benzenesulfonamide;

5-Chloro-thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;

2,5-Dichloro-thiophene-3-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;

10 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-fluoro-benzenesulfonamide;

15 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-fluoro-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2,4-difluoro-benzenesulfonamide;

20 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-difluoro-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2,6-difluoro-benzenesulfonamide;

25 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4,*N*-diethyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methyl-benzenesulfonamide;

30 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-2,3,6-trimethyl-benzenesulfonamide;

4-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide;

5 3-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide;

2-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide;

3,4-Dichloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzenesulfonamide;

10 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-trifluoromethyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-trifluoromethyl-benzenesulfonamide;

15 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-trifluoromethyl-benzenesulfonamide;

Thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

5-Chloro-thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

20 2,5-Dichloro-thiophene-3-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2,5-dimethoxy-benzenesulfonamide;

25 5-Bromo-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methoxy-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methoxy-4-methyl-benzenesulfonamide;

30 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-dimethoxy-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-dimethoxy-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3-methoxy-benzenesulfonamide;

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

5 *N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-fluoro-benzenesulfonamide;

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,4-difluoro-benzenesulfonamide;

10 *N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,6-difluoro-benzenesulfonamide;

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-ethyl-benzenesulfonamide;

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-isopropoxy-benzenesulfonamide;

15 *N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methyl-benzenesulfonamide;

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methyl-benzenesulfonamide;

20 4-Chloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

3-Chloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

2-Chloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

25 3,4-Dichloro-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-benzenesulfonamide;

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-trifluoromethyl-benzenesulfonamide;

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-trifluoromethyl-benzenesulfonamide;

30 5-Chloro-thiophene-2-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

2,5-Dichloro-thiophene-3-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-benzenesulfonamide;

5 *N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-benzenesulfonamide;

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,5-dimethoxy-benzenesulfonamide;

10 *N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4-methyl-benzenesulfonamide;

*N*-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4-methyl-benzenesulfonamide;

*N*-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-dimethoxy-benzenesulfonamide;

15 *N*-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-benzenesulfonamide;

1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;

2-(4-Chloro-phenyl)-*N*-ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-isobutyramide;

20 2-(3,4-Dichloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-acetamide;

2-(4-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-isobutyramide;

25 1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;

1-Phenyl-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

30 2-(4-Chloro-phenyl)-*N*-ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide;

2-(4-Chloro-phenyl)-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-isobutyramide;

2-(4-Chloro-phenyl)-*N*-cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-acetamide;

5 1-(4-Chloro-phenyl)-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

1-Phenyl-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

10 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-methoxy-benzenesulfonamide.

27. (Previously amended) A compound selected from the group consisting of:

*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-(4-methoxy-phenyl)-acetamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-methoxy-*N*-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-dimethoxy-*N*-methyl-benzenesulfonamide;

20 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-methoxy-4,4-dimethyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-fluoro-*N*-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3-fluoro-*N*-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-fluoro-*N*-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,4-difluoro-*N*-methyl-benzenesulfonamide;

30 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-difluoro-*N*-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,6-difluoro-*N*-methyl-benzenesulfonamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,*N*-dimethylbenzenesulfonamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2,*N*-dimethylbenzenesulfonamide;  
5    *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-4-methoxy-2,3,6,*N*-tetramethylbenzenesulfonamide;  
3-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methylbenzenesulfonamide;  
2-Chloro-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methylbenzenesulfonamide;  
10    *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-3-trifluoromethylbenzenesulfonamide;  
Thiophene-2-sulfonic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-methyl-amide;  
15    *N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-fluoro-benzenesulfonamide;  
*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-3,4-difluoro-benzenesulfonamide;  
*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-  
20    methyl-benzenesulfonamide;  
*N*-Cyclopropyl-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-trifluoromethylbenzenesulfonamide;  
Thiophene-2-sulfonic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-  
ethyl}-piperidin-4-yl)-amide;  
25    2-(3,4-Dichloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-acetamide;  
1-Phenyl-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-  
ethyl}-piperidin-4-yl)-methyl-amide;  
1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-  
30    ureido]-ethyl}-piperidin-4-yl)-methyl-amide;  
2-(4-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-  
yl)-*N*-methyl-acetamide;

*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-(4-fluoro-phenyl)-  
*N*-methyl-acetamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-methyl-2-phenyl-  
 acetamide;  
 5 2-(3-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-  
 yl)-*N*-methyl-acetamide;  
 2-(2-Chloro-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-  
 yl)-*N*-ethyl-acetamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(2-  
 10 methoxy-phenyl)-acetamide;  
 1-Phenyl-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-  
 ethyl}-piperidin-4-yl)-ethyl-amide;  
 1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid (1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-  
 ureido]-ethyl}-piperidin-4-yl)-ethyl-amide;  
 15 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-phenyl-  
 acetamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(4-  
 methoxy-phenyl)-acetamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-methoxy-  
 20 benzamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-3,4-  
 dimethoxy-benzamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-4-fluoro-  
 benzamide;  
 25 *N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(3-  
 methoxy-phenyl)-acetamide;  
 2-(3,4-Dimethoxy-phenyl)-*N*-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-  
 piperidin-4-yl)-*N*-ethyl-acetamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-thiophen-  
 30 2-yl-acetamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-2-(4-fluoro-  
 phenyl)-acetamide;  
*N*-(1-{2-[3-(2,6-Dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-*N*-ethyl-benzamide;

1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid ethyl-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide;

*N*-Ethyl-*N*-(1-{2-[3-(2-ethyl-6-methyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-2-phenyl-acetamide;

5 1-(4-Methoxy-phenyl)-cyclopropanecarboxylic acid cyclopropyl-(1-{2-[3-(2,6-dimethyl-pyridin-4-yl)-ureido]-ethyl}-piperidin-4-yl)-amide.

28. (Currently amended) A pharmaceutical composition containing a compound of any one of claims 2, 14, 17-22 or ~~25~~<sup>26</sup>-27 and pharmaceutically acceptable carrier  
10 materials and adjuvants.

29. (Cancelled).

30. (Cancelled).

31. (Cancelled).

32. (Withdrawn) The method of treating a patient suffering from a disorder associated  
15 with a dysregulation of urotensin II or urotensin II receptors, or disorders associated with vascular or myocardial dysfunction, selected from the group consisting of hypertension, atherosclerosis, angina or myocardial ischemia, congestive heart failure, cardiac insufficiency, cardiac arrhythmias, renal ischemia, chronic kidney disease, renal failure, stroke, cerebral vasospasm, cerebral ischemia, dementia, migraine.

20 Subarachnoidal hemorrhage, diabetes, diabetic arteriopathy, diabetic nephropathy, connective tissue diseases, cirrhosis, chronic obstructive pulmonary disease, high-altitude pulmonary edema, Raynaud's syndrome, portal hypertension, thyroid dysfunction, pulmonary edema, pulmonary hypertension, and pulmonary fibrosis, said method comprising administering the pharmaceutical composition according to claim  
25 28.

33. (Withdrawn) The method of claim 32, further comprising administering an additional pharmacologically active compound.

34. (Withdrawn) The method of claim 33, wherein said additional pharmacologically active compound is selected from the group consisting of ACE inhibitors, angiotensin  
30 II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, betaadrenergic antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators.

35. (Withdrawn) A method of treating a patient suffering from a disorder selected from the group consisting of restenosis after balloon or stent angioplasty, cancer, prostatic hypertrophy, erectile dysfunction, hearing loss, amaurosis, chronic bronchitis, asthma, gram negative septicemia, shock, sickle cell anemia, sickle cell acute chest syndrome, 5 glomerulonephritis, renal colic, glaucoma, therapy and prophylaxis of diabetic complications, complications of vascular or cardiac surgery or after organ transplantation, complications of cyclosporin treatment, pain, addiction, schizophrenia, Alzheimer's disease, anxiety, obsessive-compulsive behavior, epileptic seizures, stress, depression, dementias, neuromuscular disorders, and neurodegenerative diseases, said 10 method comprising administering the pharmaceutical composition of claim 28.

36. (Withdrawn) The method of claim 35, further comprising administering an additional pharmacologically active compound.

37. (Withdrawn) The method of claim 36, wherein said additional pharmacologically active compound is selected from the group consisting of ACE inhibitors, angiotensin 15 II receptor antagonists, endothelin receptor antagonists, vasopressin antagonists, betaadrenergic antagonists, alpha-adrenergic antagonists, vasopressin antagonists, TNFalpha antagonists, and peroxisome proliferator activator receptor modulators.

38. (Newly presented) A compound according to Claim 26 in free or pharmaceutically acceptable salt form.

20 39. (Newly presented) A compound according to Claim 27 in free or pharmaceutically acceptable salt form.